XBiotech Inc.

As of June 30, 2026, XBiotech, Inc. carries a market capitalization of 62.04M, placing it among publicly traded companies globally. Its enterprise value stands at -33.83M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, XBiotech, Inc. has 30.49M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, XBiotech, Inc. maintains a current ratio of 33.15, meaning it holds 33.1x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, XBiotech, Inc. posted a negative return on equity (ROE) of -29.94, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -28.90, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 86.75, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, XBiotech, Inc. recorded 238,956.90 in income tax expense. The company reported a pretax loss of -39.27M and -39.50M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, XBiotech, Inc.'s stock has declined approximately 20.55% over the past 52 weeks. The 50-day moving average sits at 1.92, while the 200-day moving average is 2.02.

Over the twelve months ended June 30, 2026, XBiotech, Inc. generated - - in revenue and converted that into -39.50M in net income, yielding earnings per share of -1.30. EBITDA reached -40.95M, while operating income came in at -42.21M.

These figures are as of June 30, 2026. Total book value stands at 112.44M, with working capital of 94.36M providing operational flexibility.

XBiotech, Inc. produced -35.62M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -126,043.20 in capital expenditures, free cash flow totaled -35.75M - equivalent to -1.17 per share.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -57.62: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield reaches - -, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to XBiotech, Inc. shareholders.

As of June 30, 2026, XBiotech, Inc. has an Altman Z-Score of 6.41, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.